US Pharma MarketingThe post Takeda reports pivotal data from FirstLight and RadiantLight trials appeared first on Clinical Trials Arena.
Takeda reports pivotal data from FirstLight and RadiantLight trials
Takeda has reported pivotal results from its Phase III FirstLight and RadiantLight studies of oveporexton, an oral OX2R-selective agonist, for the treatment of NT1. In both studies, oveporexton showed improvement at week 12 in daily functioning versus placebo across six FINI domains. The FirstLight study involved patients randomised to twice-daily 2mg, 1mg and placebo. Credit: SaiArLawKa2 / Shutterstock.com. Takeda has reported pivotal results from its Phase III FirstLight and RadiantLight studies of oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, for the treatment of narcolepsy type 1 (NT1). The trial results indicated that oveporexton led to significant improvements in…
Takeda has reported pivotal results from its Phase III FirstLight and RadiantLight studies of oveporexton, an oral OX2R-selective agonist, for the treatment of NT1.
Source: Clinical Trials Arena